Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-26T05:02:05.306Z Has data issue: false hasContentIssue false
  • English
  • Français

Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia

Published online by Cambridge University Press:  16 April 2020

Josep Maria Haro ,
Diego Novick ,
Mark Belger  and
Peter B. Jones
Josep Maria Haro*
Affiliation:
Research and Development Unit, Sant Joan de Déu-Serveis de Salut Mental, Dr. Antoni Pujades 42, 08030, Sant Boi, Barcelona, Spain
Diego Novick
Affiliation:
European Health Outcomes Research, Eli Lilly and Company Limited, Windlesham, Surrey, UK
Mark Belger
Affiliation:
European Commercialization Statistics, Eli Lilly and Company Limited, Windlesham, Surrey, UK
Peter B. Jones
Affiliation:
University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
*
* Corresponding author. E-mail address:27652jha@comb.es (J.M. Haro).
Get access

Abstract

Antipsychotic medication maintenance and the factors influencing it were analyzed using data from the SOHO study, a large observational study of the outcomes of antipsychotic treatment for schizophrenia in Europe. A total of 7186 adult patients in the outpatient setting who were initiating or changing their antipsychotic medication and who were prescribed only one antipsychotic after the baseline visit were analyzed. Medication maintenance at 12 months varied with the type of antipsychotic prescribed, being highest with clozapine (79.5%) and olanzapine (77.0%), and lowest with quetiapine (51.4%) and amisulpride (58.2%). Multiple logistic regression analysis demonstrated that the type of antipsychotic prescribed at baseline was the most important predictor of medication maintenance. Alcohol dependency, taking mood stabilizers, compulsory admission or arrest in the previous 6 months, greater clinical severity, and changing antipsychotic medication due to lack of effectiveness at baseline predicted a higher frequency of medication discontinuation in the subsequent 12 months. In contrast, medication maintenance was higher among patients who were treatment naïve at baseline, socially active or who had loss of libido at baseline. The findings from this study should be interpreted conservatively because of its non-randomized observational design.

Keywords

SchizophreniaAntipsychotic agentsTreatment outcomeEuropeMedication maintenance
Type
Original article
Information
European Psychiatry , Volume 21 , Issue 1 , January 2006 , pp. 41 - 47
Copyright
Copyright © Elsevier SAS 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aizenberg, DZemishlany, ZDorfman-Etrog, PWeizman, ASexual dysfunction in male schizophrenic patients. J. Clin. Psychiatry 1995;56:137–141.Google ScholarPubMed
Barak, YWittenberg, NNaor, SKutzuk, DWeizman, AClozapine in elderly psychiatric patients: tolerability, safety, and efficacy. Compr. Psychiatry 1999;40:320–325.CrossRefGoogle ScholarPubMed
Basile, VSMasellis, MMcIntyre, RSMeltzer, HYLieberman, JAKennedy, JLGenetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J. Clin. Psychiatry 2001;62(Suppl 23):45–66.Google ScholarPubMed
Beasley, CM Jr.Sutton, VKHamilton, SHWalker, DJDossenbach, MTaylor, CCet al.A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J. Clin. Psychopharmacol. 2003;23:582–594.CrossRefGoogle ScholarPubMed
Chakos, MLieberman, JHoffman, EBradford, DSheitman, BEffectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 2001;158:518–526.CrossRefGoogle ScholarPubMed
Csernansky, JGMahmoud, RBrenner, RRisperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 2002;346:16–22.CrossRefGoogle Scholar
Cutler, AJSexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003;28(Suppl 1):69–82.CrossRefGoogle ScholarPubMed
Davis, JMChen, NChoice of maintenance medication for schizophrenia. J. Clin. Psychiatry 2003;64(Suppl 16):24–33.Google Scholar
Davis, JMChen, NOld versus new: weighing the evidence between the first- and second-generation antipsychotics. Eur. Psychiatry 2005;20:7–14.CrossRefGoogle ScholarPubMed
Droulout, TLiraud, FVerdoux, HRelationships between insight and medication adherence in subjects with psychosis. Encephale 2003;29(5):430–437.Google ScholarPubMed
Glick, IDBerg, PHTime to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int. Clin. Psychopharmacol. 2002;17:65–68.CrossRefGoogle ScholarPubMed
Green, AICanuso, CMBrenner, MJWojcik, JDDetection and management of comorbidity in patients with schizophrenia. Psychiatr. Clin. North Am. 2003;26:115–139.CrossRefGoogle ScholarPubMed
Guy, GClinical Global Impression. ECDEU Assessment Manual for Psychopharmacology, revised Rockville, MD: National Institute of Mental Health; 1976.Google Scholar
Haro, JMEdgell, ETFrewer, PAlonso, JJones PB on behalf of the SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr. Scand. 2003;107(Suppl 416):1–9.Google Scholar
Haro, JMEdgell, ETJones, PBAlonso, JGavart, SGregor, KJet al.The European Schizophrenia Outpatient Health Outcome (SOHO) Study: rationale, methods and recruitment. Acta Psychiatr. Scand. 2003;107:222–232.CrossRefGoogle ScholarPubMed
Haro, JMEdgell, ENovick, DAlonso, JKennedy, LJones, Pet al.Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005;111:220–231.CrossRefGoogle ScholarPubMed
Haro, JMKamath, SAOchoa, SNovick, DRele, KFargas, Aet al.The clinical global impression—schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. 2003;107:16–23 (Suppl 416).CrossRefGoogle Scholar
Lambert, MHaro, JMNovick, DEdgell, ETKennedy, LRatcliffe, Met al.Olanzapine versus other antipsychotics in actual outpatient settings: 6-month safety results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005;111:232–243.CrossRefGoogle Scholar
Marder, SRGlynn, SMWirshing, WCWirshing, DARoss, DWidmark, Cet al.Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am. J. Psychiatry 2003;160:1405–1412.CrossRefGoogle ScholarPubMed
Perkins, DOPredictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 2002;63:1121–1128.CrossRefGoogle ScholarPubMed
Raja, MAzzoni, ASexual behavior and sexual problems among patients with severe chronic psychoses. Eur. Psychiatry 2003;18:70–76.CrossRefGoogle ScholarPubMed
Robinson, DGWoerner, MGAlvir, JMBilder, RMHinrichsen, GALieberman, JAPredictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. 2002;57:209–219.CrossRefGoogle ScholarPubMed
Santarlasci, BMessori, AClinical trial response and dropout rates with olanzapine versus risperidone. Ann. Pharmacother. 2003;37:556–563.CrossRefGoogle ScholarPubMed
Soholm, BLublin, HLong-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study. Acta Psychiatr. Scand. 2003;107:344–350.CrossRefGoogle ScholarPubMed
Stroup, TSMcEvoy, JPSwartz, MSByerly, MJGlick, IDCanive, JMet al.The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003;29:15–31.CrossRefGoogle ScholarPubMed
Tavcar, RDernovsek, MZZvan, VChoosing antipsychotic maintenance therapy—a naturalistic study. Pharmacopsychiatry 2000;33:66–71.CrossRefGoogle ScholarPubMed
Weiss, KASmith, TEHull, JWPiper, ACHuppert, JDPredictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr. Bull. 2002;28:341–349.CrossRefGoogle ScholarPubMed
Lieberman, JAStroup, TSMcEvoy, JPSwartz, MSRosenheck, RAPerkins, DOClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N. Engl. J. Med. 2005;353:1209–1223.Google Scholar
Submit a response

Comments

No Comments have been published for this article.